Natural Product (NP) Details
| General Information of the NP (ID: NP6628) | |||||
|---|---|---|---|---|---|
| Name |
Aloin
|
||||
| Synonyms |
Barbaloin; aloin; 1415-73-2; Aloin A; Barbaloin A; Aloinum; UNII-648RW354S9; Aloin (Mixture of A and B); CHEBI:2991; MFCD00151160; 1,8-Dihydroxy-3-hydroxymethyl-10-(6-hydroxymethyl-3,4,5-trihydroxy-2-pyranyl)anthrone; Aloin [BAN]; 648RW354S9; DSSTox_CID_25967; (10S)-1,8-dihydroxy-3-(hydroxymethyl)-10-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-10H-anthracen-9-one; (1S)-1,5-anhydro-1-[(9S)-4,5-dihydroxy-2-(hydroxymethyl)-10-oxo-9,10-dihydroanthracen-9-yl]-D-glucitol; (S)-1,8-dihydroxy-3-(hydroxymethyl)-10-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)anthracen-9(10H)-one; 10-(1',5'-Anhydroglucosyl)aloe-emodin-9-anthrone; NSC631263; 10-Glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)-9(10H)-anthracenone; Barbaloin,(S); NCGC00183867-01; Aloin (Barbaloin); 8015-61-0; EINECS 215-808-0; NSC 227189; NSC 631263; Aloin, analytical standard; DSSTox_RID_81262; DSSTox_RID_82951; DSSTox_GSID_45967; DSSTox_GSID_48755; CHEMBL2103763; DTXSID0045967; SCHEMBL14837254; 10-beta-D-Glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)-9(10H)-anthracenone; 9(10H)-Anthracenone, 10-beta-D-glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)-, (10S)-; Aloin, from Curacao aloe, ~50%; HY-N0123; Tox21_111495; Tox21_113216; s2375; AKOS022168218; ZINC100018557; CCG-268870; CS-3707; NSC 407305; NSC 758464; (R)-10-beta-D-Glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)anthracen-9(10H)-one; 9(10H)-Anthracenone, 10-.beta.-D-glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)-, (S)-; CAS-1415-73-2; CAS-8015-61-0; FT-0772660; N2491; C10305; 415B732; A807778; Q413888; Aloin, from Aloe barbadensis Miller leaves, >=97%; Aloin, United States Pharmacopeia (USP) Reference Standard; UNII-W41H6S09F4 component AFHJQYHRLPMKHU-OSYMLPPYSA-N; 10-Glucopyranosyl-1,8-dihydro-3-(hydroxymethyl)-9-anthracenone; 1,8-Dihydroxy-10-(bet.-D-glucopyranosyl)-3-(hydroxymethyl)-9(10H)-anthracenone; 1,8-Dihydroxy-10-(beta-D-glucopyranosyl)-3-(hydroxymethyl)-9(10H)-anthracenone; 10-.BETA.-D-Glucopyranosyl-1,8-dihydroxy-3-(hydroxymethyl)-9(10H)-anthracenone-, 10(S)-; 10-beta-D-Glucopyranosyl-1,8-dihydroxy-3-hydroxymethyl-9(10H)-anthrone,(R)-; (10S)-1,8-dihydroxy-3-(hydroxymethyl)-10-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]-10H-anthracen-9-one; (10S)-1,8-dihydroxy-3-(hydroxymethyl)-10-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]-10H-anthracen-9-one; (10S)-3-(hydroxymethyl)-10-[(2S,3R,4R,5S,6R)-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]-1,8-bis(oxidanyl)-10H-anthracen-9-one
Click to Show/Hide
|
||||
| Species Origin | Aloe Vera ... | Click to Show/Hide | |||
| Aloe Vera | |||||
| Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C21H22O9
|
||||
| PubChem CID | |||||
| Canonical SMILES |
C1=CC2=C(C(=C1)O)C(=O)C3=C(C2C4C(C(C(C(O4)CO)O)O)O)C=C(C=C3O)CO
|
||||
| InChI |
1S/C21H22O9/c22-6-8-4-10-14(21-20(29)19(28)17(26)13(7-23)30-21)9-2-1-3-11(24)15(9)18(27)16(10)12(25)5-8/h1-5,13-14,17,19-26,28-29H,6-7H2/t13-,14+,17-,19+,20-,21+/m1/s1
|
||||
| InChIKey |
AFHJQYHRLPMKHU-OSYMLPPYSA-N
|
||||
| CAS Number |
CAS 1415-73-2
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | TG2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | TYR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | B16-F10 | CVCL_0159 | Mouse melanoma | Mus musculus | ||
| Experimental
Result(s) |
Aloin enhances cisplatin antineoplastic activity in B16-F10 melanoma cells by transglutaminase-induced differentiation. | |||||
| β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
| Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | IL19 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Secretion | IL1B | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Secretion | IL6 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Secretion | TNF | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Inhibition | DOX-induced rise in MAB | ||||
| In-vivo Model | Male Wistar rats (150-200 g, age 6-8 weeks) were used in this study. | |||||
| Experimental
Result(s) |
Aloin alleviates doxorubicin-induced cardiotoxicity in rats by abrogating oxidative stress and pro-inflammatory cytokines. | |||||
